CAJ | 학술논문

目的：前瞻性研究瑞舒伐他汀对于高血脂患者血清高迁移率族蛋白1（HMGB1）水平的影响。方法选择高血脂组患者62例及对照组32例，分别测定两组的血清总胆固醇（TC）、高密度脂蛋白（HDL-C）、甘油三酯（TG）、低密度胆固醇（LDL-C）、超敏C反应蛋白（hs-CRP）水平和HMGB1水平。并给予高血脂组患者口服舒伐他汀（10 mg/d）治疗3个月后再次检测其TC、HDL-C、TG、LDL-C、HMGB1和hs-CRP水平。结果治疗前高血脂组TC和LDL-C水平[（6.38±0.93）mmol/L和（5.67±0.77） mmol/L]显著高于对照组[（4.34±0.89）mmol/L和（2.57±0.82）mmol/L，P＜0.05]；高血脂组hs-CRP[（3.87±1.05）mg/L]和HMGB1[（5.48±1.53）ng/ml]水平亦显著高于对照组[（1.53±1.06）mg/L和（2.11±0.95） mg/ml，P＜0.05]，差异均有统计学意义。经瑞舒伐他汀治疗3个月后，高血脂组TC及LDL-C水平较治疗前下降，TC：（4.32±0.84）mmol/L vs.（6.38±0.93) mmol/L；LDL-C：（2.32±0.72）mmol/L vs.（5.67±0.77) mmol/L，差异有统计学意义（P均＜0.05）。高血脂组HMGB1和hs-CRP水平[（2.87±1.08）ng/ml和（1.92±0.69）mg/L）]较治疗前[（5.48±1.53）ng/ml和（3.87±1.05）mg/L]同样显著降低，差异有统计学意义（P均＜0.05）。结论高血脂患者血清HMGB1水平升高，而瑞舒伐他汀能降低其血清HMGB1水平。
목적：전첨성연구서서벌타정대우고혈지환자혈청고천이솔족단백1（HMGB1）수평적영향。방법선택고혈지조환자62례급대조조32례，분별측정량조적혈청총담고순（TC）、고밀도지단백（HDL-C）、감유삼지（TG）、저밀도담고순（LDL-C）、초민C반응단백（hs-CRP）수평화HMGB1수평。병급여고혈지조환자구복서벌타정（10 mg/d）치료3개월후재차검측기TC、HDL-C、TG、LDL-C、HMGB1화hs-CRP수평。결과치료전고혈지조TC화LDL-C수평[（6.38±0.93）mmol/L화（5.67±0.77） mmol/L]현저고우대조조[（4.34±0.89）mmol/L화（2.57±0.82）mmol/L，P＜0.05]；고혈지조hs-CRP[（3.87±1.05）mg/L]화HMGB1[（5.48±1.53）ng/ml]수평역현저고우대조조[（1.53±1.06）mg/L화（2.11±0.95） mg/ml，P＜0.05]，차이균유통계학의의。경서서벌타정치료3개월후，고혈지조TC급LDL-C수평교치료전하강，TC：（4.32±0.84）mmol/L vs.（6.38±0.93) mmol/L；LDL-C：（2.32±0.72）mmol/L vs.（5.67±0.77) mmol/L，차이유통계학의의（P균＜0.05）。고혈지조HMGB1화hs-CRP수평[（2.87±1.08）ng/ml화（1.92±0.69）mg/L）]교치료전[（5.48±1.53）ng/ml화（3.87±1.05）mg/L]동양현저강저，차이유통계학의의（P균＜0.05）。결론고혈지환자혈청HMGB1수평승고，이서서벌타정능강저기혈청HMGB1수평。
Objective To investigate the effects of rosuvastatin on serum HMGB1 level in patients with hyperlipidemia. Methods 62 cases of patients with hyperlipidemia were enrolled in treatment group and 32 cases were enrolled in the control group, the serum levels of total cholesterol(TC), high density lipoprotein (HDL-C), triglyceride(TG), low density lipoprotein cholesterol (LDL-C), high sensitive C reactive protein (hs-CRP) and high mobility group protein 1 (HMGB1) were measured in two groups. After treatment with rosuvastatin (10 mg/days) for 3 months in the hyperlipidemia group, the TC,HDL-C,TG,LDL-C,hs-CRP and HMGB1 levels were measured again. Results The TC and LDL-C levels in hyperlipidemia group [(6.38±0.93)mmol/L and (5.67±0.77) mmol/L] were significantly higher than those in control group [(4.34±0.89) mmol/L and (2.57±0.82) mmol/L, respectively](both P<0.05); The hs-CRP [(3.87±1.05)mg/L] and HMGB1 [(5.48±1.53)ng/ml] levels were significantly higher than those in the control group [(1.53±1.06)mg/L and (2.11±0.95)mg/ml, respectively](both P<0.05). After treatment with rosuvastatin, the TC and LDL-C levels in the hyperlipemia group significantly decreased compared with baseline [TC:(4.32±0.84) mmol/L vs. (6.38±0.93) mmol/L and LDL-C:(2.32±0.72) mmol/L vs. (5.67 ± 0.77)mmol/L, respectively](both P<0.05).The HMGB1 and hs-CRP levels[ (2.87 ± 1.08) ng/ml and (1.92 ± 0.69)mg/L]also decreased compared with baseline[(5.48 ± 1.53) ng/ml and (3.87 ± 1.05) mg/L, respectively](both P<0.05). Conclusion Serum HMGB1 levels are increased in patients with hyperlipidemia and could be reduced by rosuvastatin.